Express Mail Label No.: EV399525472US 06-09

06-09-04

Attorney Docket No.: 21882-517 UTIL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ADAPPLICANTS:

Bertilsson et al.

SERIAL NUMBER:

10/718,071

EXAMINER:

Not Yet Assigned

FILING DATE:

November 20, 2003

ART UNIT:

1617

For:

COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (2 pages), in duplicate;
- 3. Cited References C1-C26; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 21882-517 UTIL. Please address all correspondence to customer number 35437. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor Elrifi, Reg. No. 39,529

Caryn DeHoratius, Reg. No. 45,881

Attorney/Agent for Applicant

c/o MINTZ, LEVIN, COHN, FERRIS

GLOVSKY & POPEO P.C.

Chrysler Center 666 Third Avenue

New York, New York 10017

Phone: (212) 935-3000

Fax: (212) 983-3115

Dated: June 7, 2004

Express Mail Label No.: EV399525472US Attorney Docket No.: 21882-517 UTIL

Date of Deposit: June 7, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PPLICANTS:

Bertilsson et al.

SERIAL NUMBER:

10/718,071

EXAMINER: Not Yet Assigned

FILING DATE:

November 20, 2003

ART UNIT:

1617

For:

COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Applicants: Bertilsson et al. U.S.S.N.: 10/718,071

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due to Deposit Account No. 50-0311, Reference No. 21882-517 UTIL.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Caryn DeHoratius, Reg. No. 45,881 Attorney/Agent for Applicant

c/o MINTZ, LEVIN, COHN, FERRIS

GLOVSKY & POPEO P.C.

Chrysler Center 666 Third Avenue


New York, New York 10017

Tel: (212) 935-3000 Fax: (212) 983-3115

Dated: June 7, 2004

Express Mail Label No.: EV399525472US

Date of Deposit: June 7, 2004





Attorney Docket No.: 21882-517 UTIL

PTO/SB (12-97) OMB 0651-0031 OF COMMERCE IB control number.

Patent and Trademark Office: U.S. DEPARTMENT OF COMM
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control r

Modified Form 1449/PTO	Application Number	10/718,071
	Filing Date	11/20/03
INFORMATION DISCLOSURE	First Named Inventor	Bertilsson
STATEMENT BY APPLICANT	Group Art Unit	1617
	Examiner Name	Not Yet Assigned
(use as many sheets as necessary)	Attorney Docket Number	21882-517 UTIL

				U.S. PATENT DOCUMENTS			
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

i parit		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Asanuma et al. (1996). <i>Mol. Brain Res</i> . <u>41</u> : 210-215.
	C2	Cameron and McKay (1998). Current Opinion in Neurobiol. 8: 677-680.
	C3	Cassidy and Frisen (2001). <i>Nature</i> <u>412</u> : 690-691.
	C4	Dinter et al. (1997). <i>J. Mol. Med.</i> <u>75</u> : 95-102.
	C5	D'Sa and Duman (2002). Bipolar Disorders 4: 183-194.
	C6	Duman et al. (2001). J. Pharmacol. and Ex. Therapeutics 299: 401-407.
	C7	Duman et al. (2001). Neuropsychopharmacol 25: 836-844.
	C8	Duprat et al. (2000). <i>Mol. Pharmacol.</i> <u>57</u> : 906-912.
	C9	Hallbergson et al. (2003). J. Clinical Investigation 112: 1128-1133.
	C10	Hartikka et al. (1992). J. Neuroscience Res. <u>32</u> : 190-201.
	C11	Iona et al. (1998). <i>Mol. Pharmacol</i> . <u>53</u> : 23-32.
	C12	Kim et al. (2000). Society for Neuroscience 26: 2316, Abstract No. 868.2.
	C13	Malberg et al. (2000). <i>J. Neuroscience</i> <u>20</u> : 9104-9110.
	C14	Maric et al. (2000). Cerebral Cortex 10: 561-573.
	C15	Nakagawa et al. (2002). <i>J. Neuroscience</i> <u>22</u> : 3673-3682.
	C16	Nash and Brotchie (2000). <i>J. Neuroscience</i> <u>20</u> : 7782-7789.
	C17	Pahan et al. (1997). J. Biol. Chem. <u>272</u> : 7786-7791.
	C18	Palmer (1985). Life Sciences <u>36</u> : 1995-2006.
	C19	Sakaki et al. (1997). <i>J. Neurobiology</i> <u>32</u> : 62-68.
	C20	Sugioka et al.(1996). <i>J. Physiology</i> <u>493</u> : 855-863.
	C21	Sugioka et al. (1999). Int. J. Devl. Neuroscience <u>17</u> : 163-172.
	C22	Temple (2001). Nature 414: 112-117.
	C23	Vitolo et al. (2002). <i>Proc. Natl. Acad. Sci. USA</i> <u>99</u> : 13217-13221.
	C24	Wyttenbach et al. (2001). <i>Human Mol. Genetics</i> <u>10</u> : 1829-1845.

Express Mail Label No.: EV399525472US	Attorney Docket No.: 21882-517 UTIL
Date of Deposit: June 7, 2004	

Exam Initials				
	C25	Yamashita et al. (1994). <i>J. Neurobiology</i> <u>25</u> : 1144-1153.		
	C26	Yamashita and Sugioka (1998). News Physiol. Sci. 13: 75-79.		

Serial No. ______, filed ______, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	·
-----------------------	--	--------------------	---

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

NYC 281429v1